Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Sagimet Biosciences Inc.NASDAQ: SGMT
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) rises 2.6% from a year ago
Property, plant & equipment (net) stood at $39K at the end of Q1 FY2026, up 2.6% from a year earlier and down 50.0% from the prior quarter. Over 3 fiscal years it compounded at -28.3% a year.
Context
- Property, plant & equipment (net) amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Property, plant & equipment (net) increased in 2 of the last 3 fiscal years.
What to watch
Whether property, plant & equipment (net) keeps rising in the next quarterly balance sheet after a +2.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 78K USD
- Year-over-year change
- +1.3%
- 4-year CAGR
- -30.9%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 78K | +1.3% |
| FY2024 | 2024-12-31 | 77K | +5.5% |
| FY2023 | 2023-12-31 | 73K | -65.6% |
| FY2022 | 2022-12-31 | 212K | -38.0% |
| FY2021 | 2021-12-31 | 342K | — |
Property, Plant & Equipment (Net) vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 property, plant & equipment (net) of $39K is the lowest of the 11 companies compared; the peer median is $29.3M.
- Its year-over-year change of +2.6% is the 4th highest of 11, against a peer median of -15.9%.
- Property, plant & equipment (net) amounts to 0.0% of total assets for SGMT, versus a peer median of 6.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.17B | +89896.8% | -9.7% | 1.9% | |
| Mar 2026 | $65.26M | -17.5% | +27.1% | 19.5% | |
| Mar 2026 | $46.08M | +23.2% | -1.6% | 41.7% | |
| Mar 2026 | $39.43M | -14.4% | +7.7% | 18.0% | |
| Mar 2026 | $32.1M | +1.8% | -12.7% | 14.4% | |
| Mar 2026 | $26.5M | -23.4% | -14.8% | 10.8% | |
| Mar 2026 | $2.58M | -18.7% | -11.5% | 1.1% | |
| Mar 2026 | $831K | -55.4% | -35.6% | 0.3% | |
ZURAZura Bio Limited | Mar 2026 | $125K | +17.9% | — | 0.1% |
| Mar 2026 | $49K | -53.8% | -19.6% | 0.1% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $39K | +2.6% | -28.3% | 0.0% |
| Peer median (excluding SGMT) | $29.3M | -15.9% | -11.5% | 6.4% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.